Volume 72, Issue 6, Pages (September 2007)

Slides:

Advertisements

Similar presentations

M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky

Advertisements

Navdeep Tangri, Paul V.J. Komenda, Claudio Rigatto

Volume 69, Issue 1, Pages (January 2006)

Beta blockers in the management of chronic kidney disease

Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation Jordi Bover,

Mitchell H. Rosner, W. Kline Bolton Kidney International

Volume 83, Issue 3, Pages (March 2013)

FGF23 or PTH: which comes first in CKD ?

Prehypertension and chronic kidney disease: the ox or the plow?

Reassessment of the care of the patient with chronic kidney disease

John P. Middleton, Patrick H. Pun Kidney International

M. Fukagawa, S. Nakanishi, J.J. Kazama Kidney International

Volume 85, Issue 3, Pages (March 2014)

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Volume 70, Pages S21-S25 (December 2006)

D. Batlle, P. Ramadugu, M.J. Soler Kidney International

A new era in phosphate binder therapy: What are the options?

Proinflammatory effects of iron sucrose in chronic kidney disease

Volume 74, Issue 3, Pages (August 2008)

Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps Vincent M. Brandenburg, Markus.

Volume 70, Issue 11, Pages (December 2006)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Use of vitamin D in chronic kidney disease patients

Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover.

Volume 71, Issue 11, Pages (June 2007)

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S. Bianchi, R. Bigazzi, V.M. Campese

Dedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments R. Mishler, J.J. Sands, N.J. Ofsthun,

Bisphosphonate safety and efficacy in chronic kidney disease

Volume 83, Issue 5, Pages (May 2013)

Volume 71, Issue 6, Pages (March 2007)

The calcium–phosphorus in guidelines for CKD-MBD

Vitamin D receptor: A highly versatile nuclear receptor

Volume 70, Issue 12, Pages (December 2006)

Volume 88, Issue 4, Pages (October 2015)

Fructose intake as a risk factor for kidney stone disease

Volume 73, Issue 12, Pages (June 2008)

The management of CKD: A look into the future

Volume 76, Issue 6, Pages (September 2009)

Navdeep Tangri, Paul V.J. Komenda, Claudio Rigatto

The third World Kidney Day: Looking back and thinking forward

M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Methods for guideline development

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Volume 75, Issue 9, Pages (May 2009)

On vascular calcification and plasma levels of pyrophosphate

Leptin and inflammation-associated cachexia in chronic kidney disease

Cardio-Kidney-Damage: a unifying concept

Organ transplantation goes to the movies

Nanocrystals seed calcification in more ways than one

Volume 72, Issue 2, Pages (July 2007)

Pablo A. Ureña Torres, Marc De Broe Kidney International

Volume 80, Issue 10, Pages (November 2011)

Volume 69, Issue 1, Pages (January 2006)

Is it the low-protein diet or simply the salt restriction?

Volume 70, Issue 3, Pages (August 2006)

Volume 71, Issue 9, Pages (May 2007)

Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate S. Aime, C. Canavese, P. Stratta Kidney International

Recent developments in the management of secondary hyperparathyroidism

Volume 70, Issue 5, Pages (September 2006)

Volume 72, Issue 11, Pages (December 2007)

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Volume 69, Issue 8, Pages (April 2006)

Increased fetuin-A levels following treatment with a vitamin D analog

In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression B.O. Eriksen, O.C. Ingebretsen Kidney.

Cell biological and physicochemical aspects of arterial calcification

Volume 74, Issue 10, Pages (November 2008)

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Volume 72, Issue 6, Pages 663-665 (September 2007) Vascular calcification in chronic kidney disease: New developments in drug therapy S. Huybers, R.J.M. Bindels Kidney International Volume 72, Issue 6, Pages 663-665 (September 2007) DOI: 10.1038/sj.ki.5002477 Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 1 The process of vascular calcification. Vascular calcification in chronic kidney disease (CKD) is induced via both passive Ca × P deposition and active transformation of vascular smooth muscle cells (VSMCs) into an osteoblast-like phenotype. The vitamin D receptor (VDR) agonist paricalcitol is very useful in the treatment of CKD patients. Besides effectively suppressing secondary hyperthyroidism, paricalcitol is less phosphatemic and calcemic, therefore decreasing the risk for vascular calcification. Kidney International 2007 72, 663-665DOI: (10.1038/sj.ki.5002477) Copyright © 2007 International Society of Nephrology Terms and Conditions